GlassScriptPhysician profile
Ross I Palis
NPI 1669481701
$5,665.69
in general payments reported to CMS, 2019-2025
28 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $359 · 2021: $183 · 2022: $356 · 2023: $925 · 2024: $1,344 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.44 |
| Education | $100.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,589.01 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $633.18 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $520.82 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $456.95 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $357.04 | 2022-2025 | Takhzyro, Cuvitru, Hyqvia |
| Novartis Pharmaceuticals Corporation | $333.70 | 2020-2025 | |
| Genzyme Corporation | $292.21 | 2019-2025 | |
| Pfizer INC. | $246.90 | 2019-2025 | |
| Grifols USA, LLC | $171.55 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Biocryst US Sales Co., LLC | $146.55 | 2023-2025 | Orladeyo |
| Blueprint Medicines Corporation | $144.64 | 2023-2024 | Ayvakit |
| Organon LLC | $108.31 | 2025 | Vtama |
| Amgen INC. | $104.61 | 2023-2025 | Tezspire |
| Csl Behring | $93.48 | 2019-2020 | |
| Optinose US, INC. | $69.40 | 2020-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $51.83 | 2024-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $46.51 | 2025 | Neffy |
| Lilly USA, LLC | $41.68 | 2025 | Ebglyss |
| Kaleo, INC. | $36.23 | 2024 | Auvi-Q |
| Alk-Abello, INC | $32.59 | 2020-2024 | Odactra, Ragwitek, Grastek |
| Arcutis Biotherapeutics, INC. | $27.01 | 2025 | Zoryve |
| Cycle Pharmaceuticals INC | $26.87 | 2024 | Sajazir |
| Leo Pharma INC. | $25.54 | 2025 | Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.15 | 2019 | |
| Octapharma USA, INC. | $24.49 | 2025 | Octagam Immune Globulin (Human) |
| Phadia US INC. | $18.37 | 2024 | Immunocap |
| Abbvie INC. | $15.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Palis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.